Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines
The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test
The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.
NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials
The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
Payor Policy Study Reveals Progress, Challenges in Liquid Biopsy Reimbursement
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
NCCN Backs Molecular Testing for Prostate Cancer Patients in Certain Risk Groups
The group now states that men with unfavorable intermediate-risk or high-risk disease can consider testing with Myriad's Prolaris or GenomeDx's Decipher.